Syncell

Executive Summary

Syncell is a Taiwan-based life science technology company that has developed Microscoop®, a high-precision spatial proteomics platform that enables microscopy-guided purification and mass spectrometry analysis of proteins from subcellular regions. By integrating optics, photochemistry, and AI-driven software, Microscoop® delivers unbiased, deep proteomic profiling from FFPE, fresh-frozen, and cultured samples. The platform is primarily focused on oncology and immunology research, where spatial protein mapping can uncover novel biomarkers and therapeutic targets. With its ability to analyze subcellular protein distributions with unprecedented resolution, Syncell is positioned to address critical gaps in understanding disease mechanisms and drug resistance. As a private platform-stage company with 50–200 employees, Syncell is poised to capitalize on the growing demand for spatial biology tools. The company's technology offers a significant advantage over traditional bulk proteomics methods, enabling researchers to correlate protein expression with specific cellular compartments in intact tissues. With the spatial proteomics market projected to expand rapidly, Syncell's Microscoop® has the potential to become a standard tool in translational research. The company's focus on oncology and immunology aligns with key areas of high unmet medical need, and its Taiwan base provides cost-effective R&D capabilities. Looking ahead, Syncell is expected to pursue strategic partnerships with pharmaceutical companies and expand its commercial footprint, driving adoption across academic and industry labs.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch or expanded rollout of Microscoop® platform80% success
• Q4 2026Strategic partnership with a top pharmaceutical company for oncology biomarker discovery65% success
• Q1 2027Series A or B funding round to scale manufacturing and sales75% success